Skip to main content
Premium Trial:

Request an Annual Quote

Ginkgo Bioworks to Sell $100M in Stock to BTIG

NEW YORK – Ginkgo Bioworks said on Wednesday before the market open that it has sold $100 million worth of Class A common shares to BTIG.

Ginkgo said it intends to use the proceeds from the sale to offset the cash used to finance the acquisition of certain assets and liabilities of Bayer CropScience, as well as for general corporate purposes.

BTIG proposes to offer the shares from time to time on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions, or otherwise at market prices prevailing at the time of sale.

Ginkgo has granted BTIG a 30-day option to purchase up to an additional $15 million shares of Class A common stock. The offering is expected to close on or about Nov. 18.

BTIG is acting as the sole book-running manager for the offering.

On Monday, Ginkgo disclosed that as of Sept. 30, it had $1.30 billion in cash and cash equivalents. The firm went public through a special purpose acquisition corporation in September 2021, raising approximately $1.63 billion.

In Wednesday morning trading on the NYSE, shares of Ginkgo were down 8 percent at $2.45.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.